Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications

Bulletin Express04-28

Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels in accordance with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules.

The company’s English and Chinese disclosures—including annual and interim reports, notices of meetings, circulars and other shareholder materials—will be accessible on both the corporate website (hxpharma.com) and the Hong Kong Stock Exchange’s platform (www.hkexnews.hk). Printed copies will be issued only upon specific request.

Non-registered shareholders will not receive postal notifications when new documents are uploaded. Instead, they are advised to monitor the two websites directly. Those wishing to revert to hard-copy materials can submit a completed request form to the Hong Kong share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) or email 2637-ecom@vistra.com. The selected preference will remain valid until revoked.

Enquiries can be directed to Tricor’s hotline at +852 2980 1333 (Monday–Friday, 09:00–18:00, Hong Kong time) or via email to 2637-ecom@vistra.com.

The initiative, authorized by Chairman and Executive Director Dr. Kang Xinshan on behalf of the board, aligns Haixi Pharma with the exchange’s electronic communication framework while offering shareholders optional access to printed documentation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165703728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165703728","market":"us","top_or_hot":-1,"title":"Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels in accordance with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules.</p>\n<p>The company’s English and Chinese disclosures—including annual and interim reports, notices of meetings, circulars and other shareholder materials—will be accessible on both the corporate website (hxpharma.com) and the Hong Kong Stock Exchange’s platform (www.hkexnews.hk). Printed copies will be issued only upon specific request.</p>\n<p>Non-registered shareholders will not receive postal notifications when new documents are uploaded. Instead, they are advised to monitor the two websites directly. Those wishing to revert to hard-copy materials can submit a completed request form to the Hong Kong share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) or email 2637-ecom@vistra.com. The selected preference will remain valid until revoked.</p>\n<p>Enquiries can be directed to Tricor’s hotline at +852 2980 1333 (Monday–Friday, 09:00–18:00, Hong Kong time) or via email to 2637-ecom@vistra.com.</p>\n<p>The initiative, authorized by Chairman and Executive Director Dr. Kang Xinshan on behalf of the board, aligns Haixi Pharma with the exchange’s electronic communication framework while offering shareholders optional access to printed documentation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaixi Pharma Shifts to Fully Electronic Distribution of Corporate Communications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-28 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels in accordance with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules.</p>\n<p>The company’s English and Chinese disclosures—including annual and interim reports, notices of meetings, circulars and other shareholder materials—will be accessible on both the corporate website (hxpharma.com) and the Hong Kong Stock Exchange’s platform (www.hkexnews.hk). Printed copies will be issued only upon specific request.</p>\n<p>Non-registered shareholders will not receive postal notifications when new documents are uploaded. Instead, they are advised to monitor the two websites directly. Those wishing to revert to hard-copy materials can submit a completed request form to the Hong Kong share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) or email 2637-ecom@vistra.com. The selected preference will remain valid until revoked.</p>\n<p>Enquiries can be directed to Tricor’s hotline at +852 2980 1333 (Monday–Friday, 09:00–18:00, Hong Kong time) or via email to 2637-ecom@vistra.com.</p>\n<p>The initiative, authorized by Chairman and Executive Director Dr. Kang Xinshan on behalf of the board, aligns Haixi Pharma with the exchange’s electronic communication framework while offering shareholders optional access to printed documentation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1165703728","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165703728","pubTimestamp":1777382623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业转向企业通讯全电子化分发","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels in accordance with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules.\nThe company’s English and Chinese disclosures—including annual and interim reports, notices of meetings, circulars and other shareholder materials—will be accessible on both the corporate website (hxpharma.com) and the Hong Kong Stock Exchange’s platform (www.hkexnews.hk). Printed copies will be issued only upon specific request.\nNon-registered shareholders will not receive postal notifications when new documents are uploaded. Instead, they are advised to monitor the two websites directly. Those wishing to revert to hard-copy materials can submit a completed request form to the Hong Kong share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) or email 2637-ecom@vistra.com. The selected preference will remain valid until revoked.\nEnquiries can be directed to Tricor’s hotline at +852 2980 1333 (Monday–Friday, 09:00–18:00, Hong Kong time) or via email to 2637-ecom@vistra.com.\nThe initiative, authorized by Chairman and Executive Director Dr. Kang Xinshan on behalf of the board, aligns Haixi Pharma with the exchange’s electronic communication framework while offering shareholders optional access to printed documentation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165703728","isCrawlerRequest":true}